Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
Jai Moo Shin, Nayoung Kim
https://pubmed.ncbi.nlm.nih.gov/23350044/Actively Recruiting
Led by Tanta University · Updated on 2024-12-05
44
Participants Needed
1
Research Sites
8 weeks
Total Duration
Gastroesophageal reflux disease GERD is a condition where stomach acid frequently flows back into the esophagus, causing symptoms like heartburn and acid regurgitation that reduce quality of life. GERD includes nonerosive reflux disease NERD without visible esophageal injury and erosive esophagitis characterized by esophageal damage. This study aims to compare the possible effectiveness of vonoprazan, a newer acid blocker, with pantoprazole, a proton pump inhibitor PPI, in treating GERD symptoms and improving patient quality of life. Participants will be randomly assigned to one of two groups one group will receive vonoprazan 20 mg daily along with a placebo for pantoprazole, and the other group will receive pantoprazole 40 mg daily with a placebo for vonoprazan. Both treatments will be given for 8 weeks. Vonoprazan works by blocking acid production more rapidly and potently than PPIs, which require dosing before meals. This study evaluates these two medications under daily administration to determine their effects on GERD symptoms. During the study, participants will be assessed at the start and after 8 weeks using the Gastroesophageal Reflux Disease Questionnaire and biomarker measurements to track changes in symptoms and acid levels. The primary outcome is the change in a measured biomarker before and after 2 months of treatment. Safety, symptom improvement, and quality of life will be monitored throughout the study conducted by Tanta University, with participants aged 17 to 60 years included.
CONDITIONS
Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease
A
Aya Hany Abdel Aziz, Bachelor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tanta University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive daily treatment with either Vonoprazan 20 mg or Pantoprazole 40 mg for gastroesophageal reflux disease.
Regular visits during the 8-week treatment period
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jai Moo Shin, Nayoung Kim
https://pubmed.ncbi.nlm.nih.gov/23350044/Loren Laine, Prateek Sharma, Darcy J Mulford...
https://pubmed.ncbi.nlm.nih.gov/35294415/Loren Laine, Kenneth DeVault, Philip Katz...
https://pubmed.ncbi.nlm.nih.gov/36228734/Kouichi Sakurai, Hiroko Suda, Satomi Fujie...
https://pubmed.ncbi.nlm.nih.gov/30415407/F Pace, C Negrini, I Wiklund...
https://pubmed.ncbi.nlm.nih.gov/16098002/N A Koloski, M Jones, J Hammer...
https://pubmed.ncbi.nlm.nih.gov/28551709/Michio Hongo, Yoshikazu Kinoshita, Hiroto Miwa...
https://pubmed.ncbi.nlm.nih.gov/19107335/Yousef Abdel-Aziz, David C Metz, Colin W Howden
https://pubmed.ncbi.nlm.nih.gov/33592125/Annamaria Altomare, Michele Pier Luca Guarino, Silvia Cocca...
https://pubmed.ncbi.nlm.nih.gov/24151376/Yong Sung Kim, Tae Hyeon Kim, Chang Soo Choi...
https://pubmed.ncbi.nlm.nih.gov/16015691/Tanta University
Lead Sponsor